Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

BACKGROUND: We designed a single-arm, open-label phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy (#NCT02449538). METHODS: Everolimus was administered orally at a daily dose of 10 mg continuously (28-day...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Kang, Won Ki, Lim, Ho Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363054/
https://www.ncbi.nlm.nih.gov/pubmed/28330462
http://dx.doi.org/10.1186/s12885-017-3196-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363054/
https://www.ncbi.nlm.nih.gov/pubmed/28330462
http://dx.doi.org/10.1186/s12885-017-3196-6

Ejemplares similares